ResMed releases investor presentation outlining connected sleep, breathing health strategy and growth outlook

ResMed

ResMed

RMD

0.00
  • ResMed outlined a high-single-digit revenue growth outlook, targeting earnings growth above revenue growth under its 2030 strategy.
  • Trailing 12-month 3Q26 revenue of $5.5 billion; operating margin of 34% GAAP, 36% non-GAAP.
  • Free cash flow of $1.75 billion for the trailing 12-month 3Q26 period; net cash position of about $996 million as of 3Q26.
  • Closed Noctrix acquisition for $340 million; targets refractory moderate-to-severe restless leg syndrome; annual run-rate revenue of about $24 million.
  • Raised annual dividend 13% to $2.40 per share for FY26; repurchased $500 million year-to-date, planning at least $200 million in Q4.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief on June 02, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.